Core Insights - Pulmonx Corporation reported a transition period in its performance but sees significant opportunities to regain momentum through a focused operating plan aimed at commercial growth and clinical advancements [3] Financial Performance Fourth Quarter 2025 - Total worldwide revenue was $22.6 million, a 5% decrease from $23.8 million in Q4 2024, and a 7% decrease on a constant currency basis [4] - U.S. revenue decreased by 11% to $14.1 million, while international revenue increased by 8% to $8.5 million [4] - Gross profit was $17.5 million with a gross margin of 78%, up from 74% in Q4 2024 [5] - Operating expenses decreased by 11% to $27.4 million [5] - Net loss was $10.4 million, or $0.25 per share, an improvement from a net loss of $13.2 million, or $0.33 per share, in Q4 2024 [6] Full Year 2025 - Total worldwide revenue for 2025 was $90.5 million, an 8% increase from $83.8 million in 2024, and a 7% increase on a constant currency basis [7] - U.S. revenue increased by 1% to $57.0 million, while international revenue surged by 23% to $33.5 million [7] - Gross profit for the year was $67.1 million, an 8% increase compared to $62.0 million in 2024 [8] - Operating expenses rose slightly by 1% to $120.8 million [8] - Net loss for the year was $54.0 million, or $1.33 per share, an improvement from a net loss of $56.4 million, or $1.44 per share, in 2024 [9] Future Guidance - Pulmonx expects revenue for the full year 2026 to be in the range of $90 million to $92 million [10] - The company anticipates a gross margin of approximately 75% for 2026 [12] - Total operating expenses for 2026 are expected to be between $113 million and $115 million, including about $21 million in non-cash stock-based compensation [12] - Cash, cash equivalents, and marketable securities are projected to decrease by approximately $23 million for 2026 [12] Strategic Initiatives - The company has refinanced existing debt, securing up to $60 million in committed capital under a new 5-year interest-only credit facility [11] - A cost restructuring initiative has been executed to reduce operating expenses while maintaining key investments in commercial and clinical growth [11]

Core Viewpoint - Pulmonx Corporation has successfully closed a five-year credit facility of up to $60 million with Perceptive Advisors, aimed at strengthening its capital structure and extending debt maturity to 2031 [1][2][3] Financing Details - The credit facility includes an initial $40 million term loan drawn at closing to refinance existing debt, with an option for an additional $20 million available until the end of 2027, contingent on achieving specific revenue milestones [2] - The facility is interest-only until maturity in 2031, with an interest rate set at one-month Term SOFR plus 7.0%, subject to a 3.75% floor, and allows for 2.0% of the interest to be paid-in-kind for three years [2] Strategic Implications - The new debt facility is expected to enhance the company's capital structure, allowing it to focus on executing its commercial strategy and advancing key clinical programs for its life-changing treatments for severe emphysema [3] - The Pulmonx Zephyr Valve is highlighted as a leading product with strong clinical evidence and broad reimbursement, addressing significant unmet needs for patients with severe emphysema [3] Company Overview - Pulmonx Corporation is a leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), with products like the Zephyr Endobronchial Valve and the Chartis Pulmonary Assessment System designed for patients with severe emphysema [5] - The Zephyr Valve has received FDA pre-market approval and is commercially available in over 25 countries, recognized as a standard treatment option for improving quality of life in severe emphysema patients [5] Partner Overview - Perceptive Advisors, founded in 1999, manages approximately $8 billion and focuses on supporting advancements in the life sciences by directing financial resources to promising healthcare technologies [7]

Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [2] - The company’s key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Reports, which are designed for patients with severe emphysema/COPD [2] - The Zephyr Valve has received FDA pre-market approval and is recognized as a "breakthrough device," being commercially available in over 25 countries and included in global treatment guidelines [2] Upcoming Events - Pulmonx will present at the Canaccord Genuity 45th Annual Growth Conference in Boston on August 12, 2025, at 7:00 AM PT / 10:00 AM ET [1] - A live and archived webcast of the presentation will be accessible on the "Investors" section of the Pulmonx website [1]

Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [3] - The company’s key products include the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX Platform, and StratX® Lung Analysis Reports, which are designed for patients with severe emphysema/COPD [3] - The Zephyr Valve has received FDA pre-market approval as a "breakthrough device" and is commercially available in over 25 countries [3] Upcoming Financial Results - Pulmonx will release its financial results for the second quarter of 2025 after the close of trading on July 30, 2025 [1] - Following the results announcement, company management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results [1]

Financial Data and Key Metrics Changes - Worldwide sales for Q4 2024 reached $23.8 million, reflecting a 23% growth year-over-year [9][42] - U.S. sales in Q4 were $15.9 million, representing a 16% increase compared to the same period last year [9][43] - International sales in Q4 were $7.9 million, showing a 42% year-over-year growth [9][43] - Full year 2024 worldwide revenue was $83.8 million, a 22% increase over 2023 [9][43] - Gross margin for Q4 2024 was 74%, slightly down from 75% in the prior year [44] - Net loss for Q4 2024 was $13.2 million, improving from a loss of $13.9 million in Q4 2023 [48] Business Line Data and Key Metrics Changes - The company added 52 new centers in 2024, ending the year with 283 active accounts [10] - The LungTrax platform was piloted to streamline workflows and identify eligible patients [11] - The AeriSeal CONVERT II trial was launched, expected to expand the addressable market [12][37] Market Data and Key Metrics Changes - International revenue for fiscal year 2024 was $27.3 million, a 20% increase over 2023 [44] - Strong growth was noted in major European markets and recurring orders from a new distributor in China [34][75] Company Strategy and Development Direction - The company aims to drive sustainable growth of at least 20% over the long term through initiatives focused on patient acquisition, testing, and treatment [12][15] - The strategy includes enhancing physician education and expanding geographic reach [14][21] - The company is exploring new patient acquisition channels through hospital systems [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow breakeven with current cash reserves [49] - The company anticipates strong international growth in the first half of 2025, with a re-acceleration of U.S. growth in the second half [52] - Management expects gross margins to trend higher in the second half of 2025 due to increased production volumes [53][106] Other Important Information - The company ended Q4 2024 with $101.5 million in cash, a decrease from the previous quarter [49] - Adjusted EBITDA loss for Q4 2024 was $7.5 million, an improvement from $8.4 million in Q4 2023 [48] Q&A Session Summary Question: Guidance for 2025 growth rates - Management expects strong international growth in the first half and acceleration in the second half, but does not provide specific growth rates for each half [58][60] Question: Insights on LungTraX pilot program - Feedback from pilot sites indicates positive results in identifying new patients, with integration and interface functioning well [62][64] Question: International business growth and ASP changes - No significant stocking orders were noted; growth was driven by recurring business and strong performance in Europe and China [71][75] Question: Operating expenses versus revenue growth - Management expects to continue driving leverage, with revenue growth outpacing expense growth [92][94] Question: Measuring investments in new centers and campaigns - The company tracks patient acquisition through direct-to-patient advertising and measures the effectiveness of new hires in the COPD community [96][100] Question: Gross margin outlook - Gross margins are expected to fluctuate based on geographic mix and production costs, with a long-term expectation of improvement [102][106] Question: Impact of hospitalizations on procedures - No significant impact on procedures has been observed, but there may be opportunities to identify additional patients through hospital systems [108]